The FDA just approved a new treatment for a devastating disease. The price tag is more than $2 million.
Trending News
Reuters
CEO Vas Narasimhan of Swiss drugmaker Novartis. Novartis' AveXis unit just got a new treatment approved in the US.
The FDA just approved a cutting-edge new treatment for a devastating rare genetic disease called spinal muscular atrophy.
The treatment, Novartis's Zolgensma, is a one-time therapy that works to treat the disease at the genetic level. That meants the drug's effects should last for a long time, though it's still not known if the treatment will be permanent.Novartis priced the product at $2.125 million, or $425,000 a year if paid over a five-year installment plan. Novartis called the price fair and reasonable on a conference call with reporters on Friday.
ICER, a group that measures the cost-effectiveness of new drugs, has said that a fair price range for Zolgensma is likely between $310,000 to $900,000, and could be up to $1.5 million.Copyright © 2021. Times Internet Limited. All rights reserved.For reprint rights. Times Syndication Service.
Next